Media coverage about Global Blood Therapeutics (NASDAQ:GBT) has trended somewhat positive this week, Accern reports. Accern rates the sentiment of media coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Global Blood Therapeutics earned a media sentiment score of 0.03 on Accern’s scale. Accern also assigned press coverage about the company an impact score of 46.5780135956665 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
These are some of the news stories that may have impacted Accern’s scoring:
Shares of GBT stock traded down $2.35 during trading hours on Friday, reaching $41.65. The company had a trading volume of 588,979 shares, compared to its average volume of 1,160,983. The company has a market cap of $2,112.99, a P/E ratio of -15.09 and a beta of 4.37. Global Blood Therapeutics has a 1-year low of $24.02 and a 1-year high of $68.05.
Global Blood Therapeutics (NASDAQ:GBT) last posted its quarterly earnings results on Tuesday, February 27th. The company reported ($0.94) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.72) by ($0.22). analysts predict that Global Blood Therapeutics will post -3.72 EPS for the current year.
Several research analysts have issued reports on the company. Oppenheimer set a $79.00 price objective on Global Blood Therapeutics and gave the stock a “buy” rating in a report on Tuesday, December 12th. Nomura upped their price objective on Global Blood Therapeutics to $91.00 and gave the stock a “buy” rating in a report on Monday, December 11th. HC Wainwright set a $73.00 price objective on Global Blood Therapeutics and gave the stock a “buy” rating in a report on Monday, December 11th. Cantor Fitzgerald set a $61.00 price objective on Global Blood Therapeutics and gave the stock a “buy” rating in a report on Monday, December 11th. Finally, Needham & Company LLC upped their price objective on Global Blood Therapeutics from $51.00 to $70.00 and gave the stock a “buy” rating in a report on Thursday, December 14th. Two analysts have rated the stock with a sell rating, one has issued a hold rating and twelve have assigned a buy rating to the company’s stock. Global Blood Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $70.69.
In other Global Blood Therapeutics news, insider Peter Radovich sold 30,000 shares of the stock in a transaction dated Tuesday, January 23rd. The stock was sold at an average price of $60.00, for a total transaction of $1,800,000.00. Following the completion of the transaction, the insider now owns 33,581 shares in the company, valued at approximately $2,014,860. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Jung Choi sold 3,000 shares of the stock in a transaction dated Friday, March 16th. The stock was sold at an average price of $54.15, for a total value of $162,450.00. Following the transaction, the insider now owns 139,277 shares of the company’s stock, valued at approximately $7,541,849.55. The disclosure for this sale can be found here. In the last 90 days, insiders sold 54,911 shares of company stock valued at $3,112,352. 5.30% of the stock is owned by corporate insiders.
COPYRIGHT VIOLATION WARNING: “Somewhat Favorable News Coverage Somewhat Unlikely to Affect Global Blood Therapeutics (GBT) Stock Price” was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this news story on another website, it was copied illegally and republished in violation of U.S. and international trademark & copyright legislation. The legal version of this news story can be read at https://www.dispatchtribunal.com/2018/04/08/global-blood-therapeutics-gbt-getting-somewhat-favorable-press-coverage-study-shows.html.
About Global Blood Therapeutics
Global Blood Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics to treat grievous blood-based disorders. Its lead product candidate is voxelotor, an oral once-daily therapy that modulates hemoglobin's affinity for oxygen, which is in Phase 3 clinical trials in adult and adolescent patients with sickle cell disease (SCD), as well as in evaluating the safety and pharmacokinetics of single and multiple doses of voxelotor in a Phase 2a clinical trial of adolescent and pediatric patients with SCD.
Receive News & Ratings for Global Blood Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.